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Abstract
Background: Oculocutaneous albinism (OCA) is a clinically and genetically heterogenic group of pigmentation
abnormalities. OCA type IV (OCA4, OMIM 606574) develops due to homozygous or compound heterozygous
mutations in the solute carrier family 45, member 2 (SLC45A2) gene. This gene encodes a membrane-associated
transport protein, which regulates tyrosinase activity and, thus, melanin content by changing melanosomal pH and
disrupting the incorporation of copper into tyrosinase.
Methods: Here we report two Hungarian siblings affected by an unusual OCA4 phenotype. After genomic DNA
was isolated from peripheral blood of the patients, the coding regions of the SLC45A2 gene were sequenced. In
silico tools were applied to identify the functional impact of the newly detected mutations.
Results: Direct sequencing of the SLC45A2 gene revealed two novel, heterozygous mutations, one missense (c.1226G
> A, p.Gly409Asp) and one nonsense (c.1459C > T, p.Gln437*), which were present in both patients, suggesting the
mutations were compound heterozygous. In silico tools suggest that these variations are disease causing mutations.
Conclusions: The newly identified mutations may affect the transmembrane domains of the protein, and could impair
transport function, resulting in decreases in both melanosomal pH and tyrosinase activity. Our study provides expands on
the mutation spectrum of the SLC45A2 gene and the genetic background of OCA4.
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Background
Oculocutaneous albinism (OCA) is a clinically and
genetically heterogenic group of rare monogenic dis-
eases characterized by reduced melanin production in
the skin, hair and/or eyes [1]. OCA symptoms can
include poor visual acuity, nystagmus, iris transillu-
mination, strabismus, photophobia, foveal hypoplasia
and misrouting of optic nerve fibers at the chiasm
[2]. All OCA forms exhibit autosomal recessive
inheritance [1].
OCA type 4 (OCA4, OMIM 606574) is a rare form of
OCA caused by mutations in the solute carrier family 45,
member 2 (SLC45A2) gene on chromosome 5p13 [3]. The
SLC45A2 gene encodes a membrane-associated transport
protein (MATP), which is located in melanosomes and
shows high sequence and structural similarity to Drosophila
melanogaster and plant sucrose transporters containing an
RXGRR motif [4, 5]. SLC45A2 knockdown reduced mel-
anin content and tyrosinase activity by acidifying the pH of
melanosomes in a human melanoma cell line, MNT-1 [6].
It has been suggested that, as a proton/sugar symporter,
MATP transports sugars from the melanosomes to the
cytoplasm using a proton gradient generated by a proton
pump. Thus, normal protein function ensures elevated
melanosomal pH, allowing proper binding of copper to
tyrosinase and resulting in normal tyrosinase activity [6].
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To date, 78 of the mutations identified in the SLC45A2
gene are related to OCA4 [7]. In this study, we report a
Hungarian family with two members affected by OCA4.
Our genetic investigation identified that these members
carried two novel heterozygous mutations in a com-
pound heterozygous state, expanding the mutational
spectrum of OCA4.
Methods
Patients
A Hungarian family with two affected siblings was inves-
tigated (Fig. 1). The affected individuals were 30 (Patient
II/1) and 27 years (Patient II/2) old at the time of inves-
tigation. Both exhibited pale skin, complete absence of
hair pigment, pink nevi and blue eyes with nystagmus.
This complete absence of pigmentation is unusual for
OCA4. Patient II/1 has been suffering from Crohn’s dis-
ease for 9 years and hypothyreosis for 4 years. Patient II/
2 was not aware of any known concomitant diseases.
The parents (I/1 and I/2) of the affected siblings are
clinically unaffected by OCA4. The investigated patients
declined publication of their clinical pictures.
Genetic investigation
Blood was taken from the affected patients as well as
from unrelated, healthy Hungarian individuals without
pigmentation abnormality (n = 30), and genomic DNA
was isolated using a BioRobot EZ1 DSP Workstation
(QIAGEN; Godollo, Hungary). The entire coding region
of the SLC45A2 gene and the flanking introns were amp-
lified and sequenced (primer sequences used were taken
from the UCSC Genome Browser www.genome.ucs-
c.edu). The investigation was approved by the Internal
Review Board of the University of Szeged. Written in-
formed consent was obtained from the patient and the
study was conducted according to the Principles of the
Declaration of Helsinki. After identifying the causative
mutations in the patients, further genetic screening of
the parents was declined.
Pathogenicity predictions for missense variants
In silico tools were applied to identify the functional role of
the newly found variants. Here we used SIFT (Sorting In-
tolerant from Tolerant, http://sift.jcvi.org/), PolyPhen2
(Polymorphism Phenotyping, http://genetics.bwh.harvar-
d.edu/pph2), Mutation Taster (http://www.mutationtaste-
r.org/), PredictSNP (http://loschmidt.chemi.muni.cz/
predictsnp/) PROVEAN (Protein Variation Effect Analyzer,
http://provean.jcvi.org/index.php) and PANTHER (Protein
ANalysis THrough Evolutionary Relationships, http://
www.pantherdb.org/) tools.
Results
Direct sequencing of the coding regions and the flanking
introns of the SLC45A2 gene revealed two heterozygous
mutations, one missense mutation (c.1226G >A,
p.Gly409Asp) in the sixth exon (Fig. 2a) and one nonsense
mutation (c.1459C >T, p.Gln437*) in the seventh exon
(Fig. 2b). Both patients carried both mutations, suggesting a
compound heterozygous state. Unrelated healthy controls
carried the wild type sequence. To decide, whether the de-
tected missense mutation is pathogenic, we use in silico
analysis tools (SIFT, PolyPhen2, Mutation Taster, Pre-
dictSNP, PROVEAN and PANTHER). All prediction tools
suggested that the p.Gly409Asp mutation is deleterious.
The nonsense mutation was deemed to be pathogenic. It
causes the development of a premature termination codon
at 487 amino acid position thereby the MATP protein
truncated and it may lead to its dysfunction.
Discussion
Both mutations are situated in transmembrane domains of
the MATP protein (Uniprot: Q9UMX9): the p.Gly409Asp
missense mutation is located within the ninth domain and
the p.Gln437* nonsense mutation within the tenth (Fig. 2c).
The locations of the mutations suggest that they impair the
transport function of the MATP protein. MATP dysfunc-
tion might cause an acidic melanosomal lumen, leading to
improper incorporation of copper into typrosinase. The re-
duced tyrosinase activity could, in turn, lead to the develop-
ment of the OCA phenotype [6]. The p.Gly409Asp
missense mutation affects an evolutionary conserved region
of the MATP protein (Fig. 2d), further emphasizing the
Fig. 1 Pedigree of the patients. The investigated Hungarian pedigree
spans two generations and includes two affected siblings (II/1 and II/2)
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putative pathogenic role of this mutation in the develop-
ment of the observed pigmentation abnormalities of the af-
fected patients.
Mutations of the SLC45A2 gene have been reported to
cause complete or partial loss of pigmentation, thus con-
tributing to the development of several different OCA phe-
notypes. However, a genotype–phenotype correlation based
the SLC45A2 mutations and the patients’ clinical symptoms
has not yet been established for OCA4 [8]. Mutations of
the SLC45A2 gene are typically associated with partial loss
of pigmentation, referred to as the “brown OCA” pheno-
type [7]. The two siblings reported here exhibited an un-
usual OCA4 phenotype, as they developed the complete
absence of pigmentation. This phenotype is more common
in type 1 OCA, which is caused by mutations in the tyrosin-
ase (TYR) gene. To rule out the influence of other putative
genetic-modifier variants responsible for the unusual
phenotype, the mutation screening of the TYR and OCA2
genes was also performed. Common polymorphisms of
TYR gene were detected, neither pathogenic nor non-
pathogenic variants of the OCA2 gene were identified. Pa-
tient II/1 carried the p.Ser192Tyr variant homozigously and
the p.Arg402Gln variant heterozigously. Heterozygous
p.Ser192Tyr polymorphism was identified in Patient II/2.
These two common variants of TYR gene occur at high
frequency (p.Ser192Tyr: Global MAF: 0.1234, Caucasian
MAF: 0.3718; p.Arg402Gln: Global MAF: 0.0813,
Caucasian MAF: 0.2525) but were not directly related to
pigmentation phenotypes in normal Caucasians [9]. How-
ever, functional studies reported that 192Tyr and 402Gln
alleles have reduced TYR enzyme activity. Heterozygous
p.Ser192Tyr and p.Arg402Gln variants caused significant
reduction in TYR expression, and a consistent decrease in
TYR protein levels was observed in homozygous p.Ser192-
Tyr cells [9].
Since one of our investigated OCA4 patients (II/1) is also
affected by Chron’s disease, it is possible that the mutations
of the SLC45A2 gene could be susceptibility factors for the
development of Chron’s disease. This hypothesis is further
supported by the literature, since a previous study reporting
a sister and a brother affected by congenital neutropenia
and oculocutaneous albinism identified a nonsense muta-
tion in the G6PC3 gene (c.829C >T, p.Gln277*) responsible
for the development of congenital neutropenia and
frameshift mutation in the SLC45A2 gene (c.986delC,
p.T329Rfs*68), which could explain the OCA phenotype
[10]. In this previous study, the investigated brother is also
affected by Chron’s disease, suggesting a putative associ-
ation between the mutations of the SLC45A2 gene and
Chron’s disease [10].
OCA has been considered for many years as a group of
monogenic rare diseases without cure. Accumulating
knowledge regarding the underlying mechanism of the
OCA4 might alter this viewpoint: it has been recently
Fig. 2 Identification of two novel mutations of the SLC45A2 gene. a Direct sequencing revealed a heterozygous missense mutation (c.1226G > A,
p.Gly409Asp) in the sixth exon and b a heterozygous nonsense mutation (c.1459C > T, p.Gln437*) in the seventh exon of the gene. Both mutations
were present in both affected patients. Unrelated controls (n = 30) carried the wild type sequence. c The identified mutations are located within the
transmembrane domains of the MATP protein. d The identified missense mutation is situated within an evolutionary conserved region
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demonstrated in MNT-1 cell lysates that exogenously ap-
plied copper recovers reduced tyrosinase activity resulting
from SLC45A2 knockdown [6].
Conclusions
In conclusion, we report two novel heterozygous muta-
tions, one missense and one nonsense, of the SLC45A2
gene in two Hungarian sisters affected by OCA4. The
prediction analysis and the location of the mutations as
well as the evolutionary conservation of the missense
mutation suggest a pathogenic role in the development
of OCA4. Our report, which further contributes to the
mutation spectrum of the SLC45A2 gene as well as to
the spectrum of the observed unusual clinical symptoms,
will hopefully contribute to future studies characterizing
genotype-phenotype correlations in OCA4. This study
provides expands to the genetic background of OCA4
and might serve as a basis for future studies aiming to
develop novel therapeutic approaches for OCA patients.
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